Citius Pharma Faces Nasdaq Delisting Warning

TL;DR

Nasdaq says Citius Pharma's stock price is too low, giving them 6 months to fix it or get booted.

AI Summary

Citius Pharmaceuticals, Inc. announced on September 10, 2024, that it received a notification from the Nasdaq Stock Market regarding its failure to meet the minimum bid price requirement for continued listing. The company has 180 calendar days, until March 10, 2025, to regain compliance.

Why It Matters

Failure to regain compliance could lead to Citius Pharmaceuticals' stock being delisted from the Nasdaq, potentially impacting its liquidity and investor confidence.

Risk Assessment

Risk Level: medium — The company is at risk of delisting from Nasdaq if it cannot meet the minimum bid price requirement within the specified timeframe.

Key Numbers

• 180 days — Compliance Period (Timeframe to regain minimum bid price)

Key Players & Entities

• Citius Pharmaceuticals, Inc. (company) — Registrant
• Nasdaq Stock Market (company) — Listing Exchange
• September 10, 2024 (date) — Notification Date
• March 10, 2025 (date) — Compliance Deadline

FAQ

Key Financial Figures

• $0.001 — nge on which registered Common Stock, $0.001 par value CTXR Nasdaq Capital Marke
• $1.00 — ment to maintain a minimum bid price of $1.00 per share for continued listing on The

Filing Documents

• ea0214282-8k_citius.htm (8-K) — 27KB
• 0001213900-24-077777.txt ( ) — 196KB
• ctxr-20240910.xsd (EX-101.SCH) — 3KB
• ctxr-20240910_lab.xml (EX-101.LAB) — 33KB
• ctxr-20240910_pre.xml (EX-101.PRE) — 22KB
• ea0214282-8k_citius_htm.xml (XML) — 4KB

01 Notice of Delisting or Failure to Satisfy a Continued Listing

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As previously disclosed, on September 12, 2023, Citius Pharmaceuticals, Inc. (the "Company") received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC ("Nasdaq") indicating that, based upon the closing bid price of the Company's common stock, par value $0.001 per share, for the prior 30 consecutive business days, the Company was not in compliance with the requirement to maintain a minimum bid price of $1.00 per share for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2) (the "Bid Price Rule"). At that time, the Company was provided a compliance period of 180 calendar days from the date of the original notice, or until March 11, 2024, to regain compliance with the Bid Price Rule, pursuant to Nasdaq Listing Rule 5810(c)(3)(A). On March 12, 2024, the Company received formal notice that Nasdaq granted the Company's request for an extension through September 9, 2024 to evidence compliance with the Bid Price Rule. As the Company did not regain compliance with the Bid Price Rule by September 9, 2024, the Company received a delisting determination letter on September 10, 2024. Accordingly, the Company intends to timely request a hearing before a Nasdaq Hearing Panel ("Panel"). The hearing request will automatically stay any suspension or delisting action pending the hearing and the expiration of any additional extension period granted by the Panel following the hearing. In that regard, pursuant to the Nasdaq Listing Rules, the Panel has the discretion to grant the Company an additional extension period not to exceed 180 days from the date of the delisting determination letter. There can be no assurance that the Panel will grant the Company an additional extension period or that the Company will ultimately meet all applicable requirements for continued listing on The Nasdaq Capital Market

Forward-Looking Statements

Forward-Looking Statements This Current Report contains "forward-looking identified by the use of words such as "should," "may," "intends," "anticipates," "believes," "estimates," "projects," "forecasts," "expects," "plans," "proposes" and similar expressions. Although the Company believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks, uncertainties and other important factors that could cause actual results to differ materially from such forward-looking statements, including the risk that the Company may not be successful in its appeal to the Panel, the risk that Nasdaq may not grant the Company relief from delisting, the risk that the Company may not regain compliance with the Bid Price Rule or otherwise fail to meet the requirements for continued listing under the Nasdaq Listing Rules, among other risks, uncertainties, and important factors discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended September 30, 2023, as updated by its other filings with the Securities and Exchange Commission. Forward-looking any forward-looking statements, except as may be required by law. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CITIUS PHARMACEUTICALS, INC. Date: September 11, 2024 /s/ Leonard Mazur Leonard Mazur Chairman and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR